Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.…
Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience (NASDAQ: YARW) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 7 employees.
The shares were at 12.90 USD on 20 November 2026, up 29.8% over 52 weeks. Its 52-week range is 12.38 USD to 46.95 USD: the price is 72.5% below the high and 4.2% above the low.
Its market capitalisation is 196.53M USD.
Yarrow Bioscience reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 18.67M USD.